Tag Archive for: #wilsonsdisease

Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024

/in

VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported Paris, France, June 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of interim data on its international Phase […]

Read more

Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology

/in

Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the publication of a peer reviewed paper titled ‘Treatment of Wilson Disease in Japan: An Insurance Claims Database Study’ in the Japanese Journal of Gastroenterology and Hepatology. Wilson […]

Read more

Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024

/in

Paris, France, April 23, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is pleased to announce that its management team will be participating and presenting at the following scientific and business conferences in April, May and June in 2024. Read more…

Read more

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease

/in

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease Dosing of first patient completed in Cohort 2 following Data Monitoring Committee approval to proceed Encouraging safety, tolerability and early pharmacodynamic changes observed in Cohort 1 with lead program VTX-801 Paris, France, April 8, 2024 – Vivet […]

Read more